vs

Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and CORCEPT THERAPEUTICS INC (CORT). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $110.6M, roughly 1.8× American Assets Trust, Inc.). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs 6.1%, a 5.9% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 1.8%). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs -0.1%).

Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

AAT vs CORT — Head-to-Head

Bigger by revenue
CORT
CORT
1.8× larger
CORT
$202.1M
$110.6M
AAT
Growing faster (revenue YoY)
CORT
CORT
+9.3% gap
CORT
11.1%
1.8%
AAT
Higher net margin
CORT
CORT
5.9% more per $
CORT
12.0%
6.1%
AAT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
-0.1%
AAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AAT
AAT
CORT
CORT
Revenue
$110.6M
$202.1M
Net Profit
$6.7M
$24.3M
Gross Margin
98.7%
Operating Margin
23.4%
2.2%
Net Margin
6.1%
12.0%
Revenue YoY
1.8%
11.1%
Net Profit YoY
-16.3%
-21.0%
EPS (diluted)
$0.08
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AAT
AAT
CORT
CORT
Q1 26
$110.6M
Q4 25
$110.1M
$202.1M
Q3 25
$109.6M
$207.6M
Q2 25
$107.9M
$194.4M
Q1 25
$108.6M
$157.2M
Q4 24
$113.5M
$181.9M
Q3 24
$122.8M
$182.5M
Q2 24
$110.9M
$163.8M
Net Profit
AAT
AAT
CORT
CORT
Q1 26
$6.7M
Q4 25
$24.3M
Q3 25
$4.5M
$19.7M
Q2 25
$5.5M
$35.1M
Q1 25
$42.5M
$20.5M
Q4 24
$30.7M
Q3 24
$16.7M
$47.2M
Q2 24
$11.9M
$35.5M
Gross Margin
AAT
AAT
CORT
CORT
Q1 26
Q4 25
59.4%
98.7%
Q3 25
60.5%
97.8%
Q2 25
62.6%
98.2%
Q1 25
62.0%
98.5%
Q4 24
61.3%
98.4%
Q3 24
65.5%
98.4%
Q2 24
63.6%
98.5%
Operating Margin
AAT
AAT
CORT
CORT
Q1 26
23.4%
Q4 25
21.1%
2.2%
Q3 25
22.6%
4.9%
Q2 25
24.1%
13.7%
Q1 25
66.3%
2.2%
Q4 24
26.5%
13.9%
Q3 24
30.8%
25.5%
Q2 24
27.8%
21.7%
Net Margin
AAT
AAT
CORT
CORT
Q1 26
6.1%
Q4 25
12.0%
Q3 25
4.1%
9.5%
Q2 25
5.1%
18.1%
Q1 25
39.2%
13.1%
Q4 24
16.9%
Q3 24
13.6%
25.9%
Q2 24
10.7%
21.7%
EPS (diluted)
AAT
AAT
CORT
CORT
Q1 26
$0.08
Q4 25
$0.06
$0.20
Q3 25
$0.07
$0.16
Q2 25
$0.09
$0.29
Q1 25
$0.70
$0.17
Q4 24
$0.14
$0.25
Q3 24
$0.28
$0.41
Q2 24
$0.20
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AAT
AAT
CORT
CORT
Cash + ST InvestmentsLiquidity on hand
$118.3M
$372.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1B
$647.8M
Total Assets
$2.9B
$836.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AAT
AAT
CORT
CORT
Q1 26
$118.3M
Q4 25
$129.4M
$372.2M
Q3 25
$138.7M
$421.7M
Q2 25
$143.7M
$342.2M
Q1 25
$143.9M
$322.8M
Q4 24
$425.7M
$383.3M
Q3 24
$533.0M
$380.3M
Q2 24
$114.9M
$473.2M
Total Debt
AAT
AAT
CORT
CORT
Q1 26
Q4 25
$1.7B
Q3 25
Q2 25
Q1 25
Q4 24
$2.0B
Q3 24
Q2 24
Stockholders' Equity
AAT
AAT
CORT
CORT
Q1 26
$1.1B
Q4 25
$1.2B
$647.8M
Q3 25
$1.2B
$631.9M
Q2 25
$1.2B
$635.8M
Q1 25
$1.2B
$683.3M
Q4 24
$1.2B
$679.6M
Q3 24
$1.2B
$638.8M
Q2 24
$1.2B
$596.2M
Total Assets
AAT
AAT
CORT
CORT
Q1 26
$2.9B
Q4 25
$2.9B
$836.7M
Q3 25
$2.9B
$823.6M
Q2 25
$3.0B
$801.7M
Q1 25
$3.0B
$846.5M
Q4 24
$3.3B
$840.6M
Q3 24
$3.4B
$784.3M
Q2 24
$3.0B
$714.6M
Debt / Equity
AAT
AAT
CORT
CORT
Q1 26
Q4 25
1.48×
Q3 25
Q2 25
Q1 25
Q4 24
1.72×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AAT
AAT
CORT
CORT
Operating Cash FlowLast quarter
$38.4M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
14.5%
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AAT
AAT
CORT
CORT
Q1 26
Q4 25
$167.1M
$38.4M
Q3 25
$40.5M
$54.5M
Q2 25
$49.2M
$43.9M
Q1 25
$36.9M
$5.1M
Q4 24
$207.1M
$59.3M
Q3 24
$52.4M
$73.8M
Q2 24
$59.3M
$41.2M
Free Cash Flow
AAT
AAT
CORT
CORT
Q1 26
Q4 25
$94.9M
$38.4M
Q3 25
$23.1M
Q2 25
$28.4M
$43.9M
Q1 25
$20.4M
$5.0M
Q4 24
$136.9M
$59.2M
Q3 24
$28.0M
$72.2M
Q2 24
$43.6M
$40.8M
FCF Margin
AAT
AAT
CORT
CORT
Q1 26
Q4 25
86.2%
19.0%
Q3 25
21.1%
Q2 25
26.3%
22.6%
Q1 25
18.8%
3.2%
Q4 24
120.7%
32.5%
Q3 24
22.8%
39.5%
Q2 24
39.3%
24.9%
Capex Intensity
AAT
AAT
CORT
CORT
Q1 26
14.5%
Q4 25
65.6%
0.0%
Q3 25
15.9%
0.0%
Q2 25
19.3%
0.0%
Q1 25
15.1%
0.1%
Q4 24
61.9%
0.1%
Q3 24
19.9%
0.9%
Q2 24
14.1%
0.3%
Cash Conversion
AAT
AAT
CORT
CORT
Q1 26
Q4 25
1.58×
Q3 25
8.98×
2.77×
Q2 25
9.01×
1.25×
Q1 25
0.87×
0.25×
Q4 24
1.93×
Q3 24
3.15×
1.56×
Q2 24
4.98×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AAT
AAT

Rental income$104.4M94%
Other$6.2M6%

CORT
CORT

Segment breakdown not available.

Related Comparisons